iStock_000016113842Medium

RESEARCHERS DIGEST UP STOMACH CANCER

STOMACH CANCER IS THE THIRD BIGGEST CANCER KILLER WORLDWIDE, WITH NEW THERAPIES PROVING DIFFICULT TO DEVELOP DUE TO THE DIVERSITY OF THE DISEASE, AND A CLASSIFICATION SYSTEM WHICH HAS LIMITED CLINICAL USE. HOWEVER, NEWLY PUBLISHED RESEARCH HAS BROKEN DOWN STOMACH CANCER INTO 4 BITE SIZED PORTIONS, EACH WITH THEIR OWN DISTINGUISHING FEATURES, WITH THE HOPE… Read more »

roulette

THE INCREASED ODDS OF DEVELOPING DIABETES

DUE TO INCREASING OBESITY LEVELS, INACTIVITY, AND AN AGING POPULATION WORLDWIDE THE PREVALENCE OF TYPE 2 DIABETES HAS REACHED EPIDEMIC PROPORTIONS. THE WORLD HEALTH ORGANIZATION REPORTS THAT 347 MILLION PEOPLE GLOBALLY HAVE DIABETES, WITH TYPE 2 ACCOUNTING FOR 90% OF CASES. WHILST TYPE 2 DIABETES PREVALENCE RATES HAVE BEEN INCREASING IN THE US RECENTLY, (FROM… Read more »

iStock_000026471675Medium-638x300

MERCK FIRST PAST THE US POST IN ANTI-PD-1 THERAPIES

IMMUNOTHERAPY IS AT THE FOREFRONT OF ONCOLOGY RESEARCH, WITH MANY COMPANIES FOCUSING ON THE SAME SPECIFIC TARGETS IN MULTIPLE CANCER TYPES. THE RACE HAS BEEN ON FOR THE FIRST US APPROVAL OF AN ANTI-PD-1 AGENT, AND MERCK HAVE PROVED VICTORIOUS WITH THE FDA SAYING YES TO KEYTRUDA (PEMBROLIZUMAB) IN ADVANCED MELANOMA JUST LAST WEEK. Anti… Read more »

jumpingnarrow-638x300

激活胶质母细胞瘤的免疫系统

过去,肿瘤的放射治疗是基于放射线可以杀死细胞并且可以选择性地针对肿瘤组织发挥作用。最近出现了一种新的治疗模式,即将放射疗法与目前火热的免疫疗法相结合来探索其带来的治疗优势以延长病人生存期。最近该领域的临床前研究表明,三联疗法(是指利用局部病灶放射治疗和两种免疫治疗剂相结合来促进治疗效果)显著提高了恶性胶质瘤患者的生存期…

squarepeg-round-hole-cropped-638x300

FIND THE RIGHT WAY TO USE PDX IN PERSONALIZED MEDICINE RESEARCH

PERSONALIZED MEDICINE IS THE FUTURE OF CANCER THERAPY, AND MANY TECHNIQUES ARE BEING USED TO DRIVE FORWARD RESEARCH IN THIS AREA. PATIENT-DERIVED XENOGRAFT (PDX) MODELS ARE AT THE FOREFRONT OF PERSONALIZED MEDICINE RESEARCH IN HUMAN SURROGATE TRIALS, BUT OTHER APPROACHES TO USING PDX ARE ALSO BEING PIONEERED WHICH MAY NOT BRING THE FULL PATIENT BENEFIT… Read more »